Clinical Trial

A Study of GR1802 in Participants With Chronic Sinusitis With Nasal Polyps

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to learn if GR1802 works to treat severe chronic rhinosinusitis with nasal polyps (CRSwNP) in adults. It will also learn about the safety of GR1802. The main questions it aims to answer are: 1. Does GR1802 reduce the need for surgery and systemic corticosteroid use？ 2. What medical problems do participants have when taking GR1802? Researchers will compare GR1802 to a placebo (a look-alike substance that contains no drug) to see if GR1802 works to treat CRSwNP. Participants will: Take GR1802 or a placebo once every 2 weeks for 13months. Visit the clinic once every 2 weeks for checkups and tests. Keep a diary of their symptoms and the dosage and number of times they use mometasone furoate nasal spray.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-07-18; most recent amendment 2026-02-28.
Status change: Recruiting → Active, Not Recruiting 2026-02-28
Status change: Not Yet Recruiting → Recruiting 2025-07-17
Trial Details
NCT Number NCT06516302
Lead Sponsor Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Conditions Chronic Rhinosinusitis With Nasal Polyps
Enrollment 228 participants
Start Date 2024-09-19
Primary Completion 2026-03 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2026-03-03